Key Findings
Candel Therapeutics has reported highly encouraging positive results from its Phase 2a clinical trial of aglatimagene besadenovec for non-small cell lung cancer (NSCLC), achieving a median overall survival (OS) of 24.5 months. This outcome represents a substantial improvement over historical benchmarks ranging from 9.8 to 11.8 months. The company is now targeting a Biologics License Application (BLA) submission in Q4 2026.
Technical / Clinical Details
Aglatimagene besadenovec is an oncolytic viral immunotherapy designed to induce an anti-tumor immune response within the tumor microenvironment. In the Phase 2a NSCLC trial, the investigational therapy demonstrated a median OS of 24.5 months, nearly doubling the survival rates observed with previous standard-of-care treatments. This robust efficacy data suggests a profound clinical benefit for patients with advanced NSCLC. Furthermore, comprehensive clinical and biomarker data were presented for aglatimagene in intermediate-risk localized prostate cancer, where it showed durable immune activation and a 41% reduction in recurrence risk. The safety profile across both indications was manageable, with no unexpected severe adverse events reported, supporting the therapy’s potential for broad clinical application.
Background & Context
NSCLC remains a leading cause of cancer-related mortality globally, particularly in advanced stages where treatment options have historically offered limited survival benefits. The achievement of a median OS exceeding two years for aglatimagene besadenovec signifies a potential paradigm shift in NSCLC therapy, challenging the long-standing benchmarks of under one year. This success further validates the growing role of oncolytic viruses and immunotherapy in cancer treatment. The positive data from prostate cancer also reinforces the versatility and efficacy of Candel’s immunotherapeutic platform, addressing significant unmet needs in both lung and prostate cancers.
Strategic Significance & Outlook
Candel Therapeutics’ intention to submit a BLA for aglatimagene besadenovec in Q4 2026 positions the therapy for potential accelerated approval and market entry. The strong clinical data, particularly the significant OS extension in NSCLC, provides a compelling case for regulatory review and could dramatically improve patient outcomes and significantly boost Candel’s market valuation. The regulatory pathway will be critical in determining the therapy’s ultimate availability, but the evidence accumulated so far is highly favorable. Anticipated next steps for the company include scaling manufacturing capabilities and developing a robust commercialization strategy to maximize the therapy’s reach and impact within the fiercely competitive oncology and regenerative medicine markets.
Source: https://www.trefis.com/data/companies/CADL
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
